Conservative approaches to the management of localized prostatic cancer
- 1 February 1993
- Vol. 71 (S3) , 970-975
- https://doi.org/10.1002/1097-0142(19930201)71:3+<970::aid-cncr2820711412>3.0.co;2-6
Abstract
The management of early stage prostatic cancer is controversial. Pertinent literature concerning the conservative management of early stage prostatic cancer by early endocrine therapy (EET) or by deferred treatment (DT) was reviewed. EET has not been systematically studied. Available evidence suggests that early stage prostatic cancer often progresses slowly and that DT results in a cancer-specific mortality of approximately 80% at 10 years. EET warrants clinical investigation. DT is a management option, at least in patients with a life expectancy of 10 years or less.Keywords
This publication has 54 references indexed in Scilit:
- New Staging Systems for Prostate CancerJournal of Urology, 1989
- Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow.Journal of Clinical Investigation, 1989
- Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasmsWorld Journal of Urology, 1987
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984
- Carcinoma of the Prostate: Biopsy and Conservative TherapyJournal of Urology, 1972
- Origin and development of carcinoma in the prostateCancer, 1969
- Endocrine Therapy in Carcinoma of the Prostate Gland: 10-Year Survival StudiesJournal of Urology, 1960
- SOME COMMENTS ON THE LONG-TERM RESULTS OF ENDOCRINE TREATMENT OF PROSTATIC CANCER1British Journal of Urology, 1958
- STUDIES ON PROSTATIC CANCERArchives of Surgery, 1941
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889